BB Biotech AG
New innovative drugs and technologies are powering sustainable momentum in the biotech sector
Focus on profitable companies and small and mid-cap companies with strong pipelines
Attractive dividend policy; Dividend payment of 5% p.a.
Investment Focus
ISIN-No. CH0038389992
BB Biotech aims to achieve an average annual double-digit return over the long term, thus outperforming the broad market indices by a significant margin. BB Biotech invests worldwide in fast growing companies developing and marketing innovative biotech drugs.
Indexed performance (as at: 28.03.2024)
Share price: CHF 45.20 (27.03.2024)
NAV: CHF 45.65 (27.03.2024)
Rolling performance (27.03.2024)
Share Price | NAV | Benchmark | |
27.03.2023 - 27.03.2024 | -5.79% | 19.66% | 9.73% |
25.03.2022 - 27.03.2023 | -18.16% | -13.91% | -2.38% |
26.03.2021 - 25.03.2022 | -16.71% | -23.00% | -12.60% |
27.03.2020 - 26.03.2021 | 64.60% | 67.04% | 41.25% |
Annualized performance (27.03.2024)
Share Price | NAV | Benchmark | |
1 year | -5.79% | 19.66% | 9.73% |
3 years | -13.70% | -7.42% | -2.17% |
5 years | -2.82% | -0.13% | 4.17% |
10 years | 9.21% | 7.86% | 6.89% |
Since Inception p.a. | 10.69% | 10.72% | 9.14% |
Cumulative performance (27.03.2024)
Share Price | NAV | Benchmark | |
1M | 0.53% | -2.09% | -0.20% |
YTD | 10.41% | 12.59% | 10.03% |
1 year | -5.79% | 19.66% | 9.73% |
3 years | -35.78% | -20.68% | -6.37% |
5 years | -13.36% | -0.65% | 22.72% |
10 years | 141.60% | 113.16% | 94.85% |
Since Inception | 2'085.83% | 2'106.35% | 1'325.37% |
Annual performance
Share Price | NAV | Benchmark | |
2023 | -18.15% | -7.39% | -4.79% |
2022 | -24.29% | -11.00% | -9.09% |
2021 | 8.34% | -11.45% | 2.98% |
2020 | 19.35% | 24.26% | 15.80% |
Facts & Key figures
Investment Focus
BB Biotech actively invests worldwide in fast growing companies developing and marketing innovative biotech drugs. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
Investment Manager | Bellevue Asset Management AG |
Custodian | Bank Julius Bär AG |
Fund Administrator | Bellevue Asset Management AG |
Auditor | Deloitte AG |
Launch date | 09.11.1993 |
Year end closing | 31. Dec |
Management Fee | 1.10% |
ISIN number | CH0038389992 |
Valor number | 3838999 |
Bloomberg | BION SW Equity |
WKN | A0NFN3 |
Legal Information
Legal form | Incorporate company |
SFDR category | Article 8 |
Key data (29.02.2024, base currency CHF)
Beta | 1.29 |
Volatility | 32.70 |
Tracking error | 14.38 |
Active share | 82.31 |
Correlation | 0.92 |
Sharpe ratio | -0.10 |
Information ratio | -0.14 |
Jensen's alpha | -1.57 |
No. of positions | 30 |
Portfolio as at 31.12.2023
Positions
Market capitalization
Breakdown by sector
Currency
Benefits & Risks
Benefits
- Unique opportunity for European investors to access the global biotech sector, a non-cyclical growth industry that is strongly supported by increasing demand, driven by demographic trends and life style changes.
- New innovative drugs and technologies are powering sustainable momentum in the biotech sector.
- Focus on a diversified portfolio of profitable companies as well as small and midcap companies with strong pipelines.
- Management Team with strong scientific and medical expertise. Renowned Board of Directors.
- Attractive dividend policy; Dividend payment of 5% p.a.
Risks
- BB Biotech actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Biotech equities can be subject to sudden substantial price movements owning to market, sector or company factors.
- BB Biotech invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The price investors pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company.
- BB Biotech may take a leverage of up to 15%, which may lead to even higher price movements compared to the underlying market.
Review / Outlook
BB Biotech published its annual report on February 16. The full report is available on our website: www.bbbiotech.ch. BB Biotech also published the agenda for its Annual General Meeting taking place on March 21, 2024. The Board of Directors proposes a dividend of CHF 2.00 per share at the upcoming Annual General Meeting, which represents a yield of 5% based on the volume-weighted average share price of December 2023. This marks a continuation of the dividend policy introduced in 2013.
BB Biotech’s Chairman, Dr. Erich Hunziker, will not stand for re-election at the Annual General Meeting and the Board proposes that Dr. Thomas von Planta takes over as Chairman. Camilla Soenderby will be nominated as a new independent board member at the general meeting; Dr. Thomas von Planta, Dr. Clive Meanwell, Laura Hamill, Dr. Pearl Huang and Prof. Dr. Mads Krogsgaard Thomsen will all stand for re-election.
Several of BB Biotech´s portfolio companies published full-year financial results during the month of February. We have highlighted selected news from some of our portfolio companies below.
Vertex Pharmaceuticals (-2.9%, in USD) and Crispr Therapeutics (+33.8%, in USD) announced on February 13, that the European Commission has granted conditional marketing authorization to CASGEVY™, a CRISPR/Cas9 gene-edited therapy. CASGEVY is approved for the treatment of patients who are 12 years of age and older with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).
Alnylam (-12.6%, in USD) announced its annual results on February 15, including updates to the statistical analysis plan for the HELIOS-B Phase III study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy. These changes include updates to the primary and secondary endpoint structure, as well as extending study exposure out to 36 months. Topline results are expected to be available in late June or early July.
Celldex Therapeutics (+36.5%, in USD) announced on February 24, positive 12 week results from their Phase II clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines. The studies will continue dosing patients until week 52. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival.
Past performance is not a reliable indicator of future results and can be misleading. Changes in the rate of exchange may have an adverse effect on prices and incomes. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. The reference benchmark is used for performance comparison purposes only (dividend reinvested). Show moreShow less